BCL2A1 is an anti-apoptotic member of the BCL-2 family that functions as a critical regulator of cell survival in hematopoietic and other cell types. Mechanistically, BCL2A1 inhibits apoptosis by modulating mitochondrial outer membrane permeability and preventing cytochrome c release 1, with expression regulated by transcriptional factors including NF-κB signaling pathways 2. BCL2A1 plays important roles in protecting cells from serum deprivation and cytokine withdrawal, particularly in hematopoietic cells 1. Clinically, BCL2A1 represents a major determinant of therapeutic resistance across multiple cancers. In acute myeloid leukemia (AML), BCL2A1 upregulation confers resistance to the BCL2 inhibitor venetoclax, a first-line therapy 34. Similarly, in gliomas, high BCL2A1 expression associates with advanced WHO grade, resistance to temozolomide chemotherapy, and unfavorable prognosis 5. In B-cell lymphomas, CARD11-driven BCL2A1 upregulation directly mediates resistance to venetoclax-based combination therapies 2. BCL2A1 also contributes to immunotherapy resistance by promoting tumor-associated macrophage infiltration in gliomas 5 and enabling melanoma cells to evade T cell cytotoxicity 6. Strategies targeting BCL2A1 downregulation through RNA splicing modulation or combination therapies show promise in overcoming drug resistance.